
NZM11
NZM11 is an adherent metastatic melanoma cell derived from a 47-year-old male patient with a subcutaneous lesion on his mid back.
[Create a profile and sign in to view pricing and add to cart]
- Description
- Ask a Question
Description
Description: NZM11 is an adherent metastatic melanoma cell derived from a 47-year-old male patient with a subcutaneous lesion on his mid back.
Description Key Words: Human metastatic melanoma
Also Known As: No other names
Organism: Human (Homo sapiens)
Tissue: Melanoma metastatic
Growth Properties: Adherent and suspension
Doubling Time: 5-6 days
Morphology: Epithelial
Growth Medium: This cell line was established by the depositor in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS)”, 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%O2, 5%CO2 and 90%N2.
At CellBank Australia it has been cultured in: Alpha modified Minimum Essential Medium (MEM) supplemented with 10% Foetal Bovine Serum (FBS)”, 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%CO2.
Resuscitation: Remove protective cryoflex layer around the ampoule prior to thawing. Thaw the ampoule by gently agitating in a 37°C waterbath; thawing should be rapid (around 2 minutes). A centrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.
Subculturing Procedure:
Medium Renewal: 2-3 times per week.
Subcultivation Ratio: 1:2 – 1:4 Seeding density 2 x104cells/cm2. Split subconfluent cultures(70-80%). Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 minutes.
Culture Conditions: Incubate the culture at 37°C with 5% CO2.
Cryoprotectant Medium: 10% DMSO + 90% FCS
Handling Procedure for Frozen Cells: Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability.
Additional Information:
- Wild-type for TP53, PIK3CA, PTEN, NRAS
- Deletion CDKN2A/B
- BRAF mutation V600E
- Sensitive to temozolomide
- MGMT not expressed
Depositor: Professor Bruce Baguley – The University of Auckland, New Zealand
Reference:
Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC.
Radiation-induced cell cycle delays and p53 status of early passage melanoma lines.
Oncol Res 2000; 12: 149-155.
PubMed 11216673
Ask a Question
Have a question about this product? Our technical team is here to help.




